Abstract
A new derivative of cephamycin antibiotic, cefotetan (CTT, YM09330), was applied to 16 inpatients at a divided dose of 1-4 g twice daily.
Among 13 cases with respiratory tract infectious diseases, cefotetan was excellent in 3 cases, good in 7cases, fair in 2 cases and poor in 1 case, showing the efficacy rate of 92.3%. In 2 cases with subacute infective endocarditis, cefotetan was excellent in 1 case and good in 1 case. In a case of perinephritis, the drug was found to be poor.
In 9 cases for which causal bacteria could be identified, bacteriological study was conducted. As a results, it was determined that H. influenzae was eradicated in 3 cases and decreased in 1 case. K. pneunomiae, S. marcescens, S. viridans and enteric GNR in each one case were all eradicated, while S. aureus persisted in 1 case.
Neither subjective nor objective side effects were observed in any case. As an abnormality in laboratory findings, a slight elevation of s-GOT and s-GPT were found in 2 cases, and also a slight elevation of s-GOT, s-GPT and Al-p was found in one case respectively, but these abnormalities returned normal immediately after discontinuation of medication.
It is suggested, therefore, that cefotetan is a useful drug for infections caused by gram-negative bacteria.
